Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Vivo Invests $60 Million in China RNAi JV it Formed with Arrowhead

publication date: Apr 25, 2022

Vivo Capital will invest $60 million in a new JV that it formed with Arrowhead Pharma, a Pasadena, CA biotech, which will have China rights to four Arrowhead RNAi candidates. The new JV, Visirna, will pay royalties on sales to Arrowhead, but will not make any upfront payments or milestones. Vivo pledged to leverage its Greater China network to support Visirna, including recruiting a leadership team while also overseeing development, clinical, and regulatory strategies in China. In the future, Visirna will develop its own RNAi drugs and in-license others. Arrowhead owns a majority stake in Visirna. More details....

Stock Symbol: (NSDQ: ARWR)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China